COMMUNIQUÉS West-GlobeNewswire

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
23/09/2026
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
23/09/2026
SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed [...]
Verano to Report Third Quarter 2026 Financial Results on October 29, 2026
23/09/2026
CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
Psyence BioMed Announces Strategic Ibogaine Investment
23/09/2026
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical [...]
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
23/09/2026
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and [...]
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
23/09/2026
John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in Singapore REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, [...]
Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million
23/09/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: [...]
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
23/09/2026
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration [...]
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
23/09/2026
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
23/09/2026
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will [...]
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
23/09/2026
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained [...]
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
23/09/2026
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its [...]
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
23/09/2026
OTTAWA, Ontario, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to continue its annual tradition of hosting an educational webinar in recognition of World Rabies Day. This year’s [...]
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
23/09/2026
OTTAWA, Ontario, 23 sept. 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de santé animale (ICSA) est fier de perpétuer sa tradition annuelle consistant à organiser un webinaire éducatif à l’occasion de la Journée mondiale [...]
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
23/09/2026
Garching / Munich, September 23 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Lumara Bio , a dedicated oncology therapeutics division of ITM, today announced that [...]
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
23/09/2026
Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development - Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of [...]
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
23/09/2026
Rabies remains one of the world’s deadliest yet preventable zoonotic diseases, highlighting the need for sustained prevention efforts. Through a new multi-year collaboration, Boehringer Ingelheim and AWARE are expanding [...]
Engitix appoints Sonia Quaratino, MD, PhD as EVP Chief Medical Officer as its ECM pipeline moves toward clinical development
23/09/2026
LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based discovery platforms to transform drug development in oncology, fibrosis and fibro‑inflammatory [...]
Actimed Therapeutics Completes Recruitment for PROACT Phase 2a Study Evaluating S-pindolol benzoate (ACM 001.1) in Obese Adults During and After Semaglutide Therapy
23/09/2026
London, UK – 23 rd September 2026. Actimed Therapeutics Ltd (“Actimed”) has successfully completed patient recruitment for the PROACT Study (Protocol ACM 001 2024 01 CT; NCT07101939), a two part, Phase 2a, randomised, [...]

Pages